The analgesic effect of intramuscular ketorolac was assessed by double blind study in forty women presenting for day-case laparoscopic sterilisation. The patients were randomly allocated to receive either ketorolac 30 mg or saline by intramuscular injection immediately following induction of general anaesthesia. There was no statistically significant difference between the groups in pain scores, opioid requirements or incidence of nausea and vomiting in the postoperative period. In view of the potential side-effects of ketorolac, and the apparent lack of efficacy when used prophylactically, the routine use of the drug in this group of patients cannot be recommended.
Economic pressures have led to increasing demand for a variety of surgical procedures to be performed in day-care surgical facilities. Laparoscopic sterilisation is one such procedure, despite being associated with a considerable degree of pain 1 and significant overnight admission rates. 2, 3 Ketorolac is one of the newer non-steroidal antiinflammatory drugs (NSAIDs) which would appear to have significant analgesic properties and is the only NSAID licensed for intramuscular use in Australia.
It would thus seem to be the ideal analgesic for day surgery, potentially causing less postoperative drowsiness, nausea and vomiting than the opioids. The purpose of the study was to determine whether ketorolac would provide adequate postoperative analgesia following laparoscopic sterilisation and whether its use would have any impact on the incidence of nausea and vomiting.
METHODS
Ethical approval for the study was obtained from The Queen Elizabeth Hospital Ethics Committee. Patients excluded from the study were those with a poor understanding of English, active asthma, renal or hepatic or peptic ulcer disease, a bleeding diathesis, allergy to NSAIDs and breast-feeding mothers. Patients who consented to be in the study were randomly "M,B.H.C.H" D,A,(S,A,). tER,C.A., EEA,R,A,C.S., EA,N.Z,C.A" Director. assigned to receive either ketorolac 30 mg or saline by intramuscular injection immediately following induction of anaesthesia. Neither the patient, anaesthetist nor the recovery staff knew whether the drug or placebo had been given.
Anaesthesia was standardised so that all patients received fentanyl 100 p.g, a sleep-inducing dose of propofol, either atracurium or vecuronium, oxygen, nitrous oxide, isoflurane, atropine 1.2 mg and neostigmine 2.5 mg. Surgery was performed by one of two surgeons who applied Hulka clips to the fallopian tubes.
Postoperative pain was assessed using a visual analogue score (VAS) on three separate occasions in Recovery. A VAS was done immediately prior to leaving first-stage recovery approximately one hour after the ketorolac injection. A subsequent VAS was done on discharge, roughly five hours after surgery. Patients were also asked to assess their worst pain since surgery on a VAS prior to being discharged. Where possible, patients were contacted by telephone the following day to enquire about pain and any other symptoms they may have experienced. Patients received analgesia using a standard intravenous fentanyl, morphine or pethidine protocol if required and the total amount was recorded. Documentation also included age, weight, duration of the procedure, time when ready for discharge and whether the attending registered nurse in the recovery ward thought the patient had received ketorolac or placebo.
Statistical analysis of demographic data and the incidence of side-effects were analysed using Student's t test. Pain scores and analgesic requirements were analysed using the Mann-Whitney U Test. The demographic data are shown in Table 1 . There was no significant difference between the two groups with respect to age, weight or procedure duration. Table 2 shows the pain scores at various times, the opioid requirements, the incidence of nausea and vomiting and the use of anti-emetics.
Assessment of pain using the VAS slightly favours the ketorolac group when patients were assessed prior to leaving the first stage recovery and prior to discharge. This, however, was not significantly different from the saline group. The worst pain scores recorded prior to discharge were similar in the two groups. There were no significant differences between the groups in those patients who were contacted by telephone the next day. On all occasions, there was an extremely wide range of scores in both groups. The attending recovery staff were unable to pick which patients had active treatment.
Opioid Requirement
The mean opioid requirement in terms of pethidine equivalents was 23.5 mg in the ketorolac group and 35.5 mg in the saline group. This difference, however, is not statistically significant. The range of opioid requirement was large in both groups, being 0-180 mg in the ketorolac group and 0-190 mg in the saline group.
Nausea and Vomiting
The occurrence of nausea was high in both groups (ketorolac 50070, saline 60070) and that of vomiting in similar ratio (ketorolac 25070, saline 35070). The differences were not statistically significant and did not correlate with amount of opioid received. Anti-emetic use was similar in both groups (ketorolac 35070, saline 45070 ).
The time until patients were ready for discharge was similar in both groups, with a mean of 4 hours 55 minutes in the ketorolac group and 5 hours 17 minutes in the saline group. No patient required overnight admission.
DISCUSSION
Laparoscopic tubal ligation has been shown to be associated with a considerable degree of pain'·2 and high overnight admission rates. 2.3 Despite this, the procedure is commonly performed in day-care surgery facilities. The major causes for either delay in discharge or overnight admission is persistent pain, followed by nausea and vomiting.' The long recovery times in this study would confirm the severe sequelae arising from laparoscopic tubal ligation.
The rationale for the use of a NSAID for analgesia following laparoscopic sterilisation is that it would be associated with less sedation, nausea and vomiting than occurs after the use of opioids. Much of the pain is thought to be mediated by the release of prostaglandins following tissue damage to the fallopian tubes,4 and therefore an anti-prostaglandin should provide effective analgesia. NSAID use for analgesia following laparoscopic sterilisation has been studied, with variable results. Edwards et al. found no benefit with the use of diclofenac. 2 Crocker and Paech found a minor non-statistically significant result with rectal indomethacin,5 whereas Comfort et al. 6 found that oral naproxen administered at least one hour prior to surgery produced significant postoperative analgesia. Ketorolac is one of the newer NSAIDs, with a supposedly greater analgesic effect and less antiinflammatory properties. It is the only NSAID available for parenteral administration in Australia, an important consideration for day surgery as there may not be sufficient time to allow for the absorption of orally administered drugs. Ketorolac has been shown to have significant opioid-sparing effect for a number of surgical procedures. 79 The efficacy of ketorolac for laparoscopy can at best be described as controversial from other studies. IO · '2 When used for laparoscopic tubal ligation, it has been found to have no fentanyl sparing effect even when given intravenously.'3 The reason for its relatively disappointing effects in our study could be attributed to insufficient time for absorption prior to the completion of surgery. Following intramuscular ketorolac the onset of pain relief occurs within ten minutes, with peak plasma levels occurring at 50 minutes. '4-16 This delay of maximal analgesic effect may have had a small impact on opioid requirement but it would not have affected the VAS taken at one hour. Any possible advantages from ketorolac administration appear to be relatively minor. Power analysis based on our findings revealed that it would be necessary to carry out a large study involving more than 186 patients in order to demonstrate a statistically significant benefit. As a result, one would have to question the wisdom of routinely administering ketorolac, with its potential side-effects, to all patients undergoing laparoscopic sterilisation as day-cases.
